To evaluate the effectiveness and safety of BAF312 compred to placebo (a substance that looks like BAF312 but does not contain any active ingredient) in people with secondary progressive multiple sclerosis (SPMS). Your participation will last for 23 to 42 months, but no more than 60 months, depending on when you enroll in the study. You would be randomized (put in a group by a chance process, like flipping a coin) to receive either BAF312 or placebo. BAF312.
Who may be Eligible
18-60 years of age; documented clinical diagnosis of SPMS; EDSS score of 3.0-6.5r; disability progression in the previous 2 years; no evidence of relapse or corticosteroid treatment 3 months prior to entering the study.
For More Information, Contact
Phone: (704) 446-1987 Fax: (704) 446-1915 Email: Bridget.email@example.com Address: Carolinas Medical Center - Department of Neurology
1010 Edgehill Road, North
Charlotte, NC 28207